Results 211 to 220 of about 38,393 (221)
Some of the next articles are maybe not open access.
The safety of thiazolidinediones
Expert Opinion on Drug Safety, 2011The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions. Many new therapies have emerged, including thiazolidinediones (TZDs), selective agonists of PPAR-γ, now used as both primary and add-on therapies. Given that T2DM is a lifetime disease, there is a need for assurance that new drugs are both safe and effective.
openaire +2 more sources
Where thiazolidinediones will fit
Diabetes/Metabolism Research and Reviews, 2002Individuals with type 2 diabetes have two defects: insulin resistance, which occurs in the first stages of disease progression, and pancreatic beta-cell failure, which occurs later in the disease. Insulin resistance is the major pathological defect. During the course of the disease, insulin levels are initially elevated to compensate for the increased ...
openaire +2 more sources
[Glitazones (thiazolidinedione)].
Revue medicale de Bruxelles, 2001Insulin resistance is the major defect in type 2 diabetes. Troglitazone is the first of a new class of drugs, the thiazolidinediones (TZD) with insulin sensitising actions. The TZD activate PPAR gamma (Peroxisome Proliferator Activated Receptor gamma). In clinical trials, the TZD decrease plasma glucose, plasma insulin and Hb A1C.
J, Ducobu, J, Sternon
openaire +1 more source
Hepatotoxicity of thiazolidinediones
Diabetes, Obesity and Metabolism, 2001W L, Isley, J C, Oki
openaire +2 more sources